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Background: Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experi-
ments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects.
Aim: To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC).
Methods: This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for cura-
tive resection of biopsy conﬁrmed single primary site CRC were randomised (n = 23) by computer-generated
code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg;
n = 12) or placebo (n = 11). The primary outcome measure was the proportion of tumour cells undergoing
apoptosis (signiﬁcant if N7% showed Tunel staining). Secondary immunohistochemical outcomes assessed
these tumour markers: VEGF, EGFR, c-MYC, CD31, Ki67 and p53, and clinical responses.
Findings: 20 patients (artesunate = 9, placebo = 11) completed the trial per protocol. Randomization groups
were comparable clinically and for tumour characteristics. Apoptosis in N7% of cells was seen in 67% and 55%
of patients in artesunate and placebo groups, respectively. Using Bayesian analysis, the probabilities of an
artesunate treatment effect reducing Ki67 and increasing CD31 expression were 0.89 and 0.79, respectively.
During a median follow up of 42 months 1 patient in the artesunate and 6 patients in the placebo group devel-
oped recurrent CRC.
Interpretation: Artesunate has anti-proliferative properties in CRC and is generally well tolerated.© 2014 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Colorectal cancer (CRC) contributes 9–10% of the annual global can-
cer burden in men (746,000 cases) and women (614,000 cases) (Ferlay
et al., 2012). In the UK, 110 new cases are diagnosed daily, with older
patients particularly at risk of death (UK CR, 2014) and with N50% of
newly diagnosed cases having locally advanced disease (T3/T4). Resec-
tion is the only curative treatment for non-metastatic CRCbut this has to
be combined with neo-adjuvant chemo- and/or radio-therapy, to
downstage more advanced presentations.g and placebo was supplied by
pen access article under the CC BY licPrognosis with best available treatments does not increase disease
free or overall survival beyond ~60% at 5 years after diagnosis. For
most patients, access to advanced treatment modalities is lacking, too
expensive to be widely available, or associated with signiﬁcant morbid-
ity thereby further compromising their survival. There is therefore a
continuing and urgent need to develop new, cheap, orally effective
and safe CRC therapies. One approach is to study existing drugs that al-
ready have some anticancer properties in experimental settings, and to
assess their safety and efﬁcacy in in vivo studies.
Artesunate is derived from artemisinin, which is extracted from
Artemisia annua L. and is a widely used antimalarial that can be ad-
ministered by oral, rectal and parenteral routes (Gomes et al., 2009;
Kremsner and Krishna, 2004; Kremsner et al., 2012; Nealon et al.,
2002; Hien et al., 1994, 1992; Jiang et al., 1982). Soon after the isolation
of artemisinin by a Chinese government's programme, the anticancer
properties of artemisinins were ﬁrst reported (Efferth et al., 2007;ense (http://creativecommons.org/licenses/by/3.0/).
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in vitro and animal models have conﬁrmed their remarkable capacity
to exert broad anti-cancer effects (Efferth et al., 2007). They reduce
cell proliferation and angiogenesis and trigger apoptosis (Anfosso
et al., 2006; Efferth et al., 2001, 1996).
There have only been isolated case reports in humans of anti-cancer
effects of artemisinins (reviewed Krishna et al., 2008). These include
cases ofmetastatic uvealmelanoma (Berger et al., 2005) laryngeal squa-
mous cell carcinoma (Singh and Verma, 2002) and pituitary macro-
adenoma (Singh and Panwar, 2006). An open-label Chinese study
treated non-small cell lung cancer patients and showed prolonged
time to cancer progression compared with controls when artesunate
was added to conventional treatment (Zhang et al., 2008), but no
beneﬁt on mortality. An open-label pilot study of patients receiving
artesunate for advanced cervical cancer suggested that it waswell toler-
ated and improved symptoms (Jansen et al., 2011). There has been a
phase II trial on the activity of artesunate in non-resectable tumours of
dogs (Rutteman et al., 2013) and efﬁcacy of extracts of A. annua in 5 vet-
erinary sarcomas (Breuer and Efferth, 2014). This study examines anti-
CRC effects and tolerability of artesunate used as monotherapy in a
rigorous study design.
2. Methods
2.1. Ethics
The trial was approved by Wandsworth Ethics Committee (Wands-
worth UK, Ref: 08/H0803/3) and was registered (ISCRTN05203252).
2.2. Trial Design
This was a single-centre, double-blind, placebo-controlled trial with
balanced randomisation of patients (1:1) conducted at the St George's
University of London, UK and St. George's Healthcare NHS Trust.
2.3. Participants for Inclusion
Eligible participants were with biopsy conﬁrmed single primary site
colorectal adenocarcinoma; aged 21–90 years; with all stages amenable
to surgical treatment and not requiring neoadjuvant treatment; with
planned curative resection; and with written, informed consent.
2.4. Exclusion Criteria
Thesewere: contraindication to use of artesunate due to hypersensi-
tivity; pregnancy; history of hearing or balance problems; immunosup-
pression or concomitant medication known to interact with artesunate
(see below); weight b50 kg or N100 kg; severe anaemia (haemoglobin
b8 g/dL); other planned intervention, apart from standard of care;
inability to give informed consent; inability or unwillingness to take ef-
fective contraception in women of child-bearing age; chronic kidney
disease of NKF D/QOFI stage 3 or above (eGFR b 60 mL/min); bilirubin
N2 of the upper limit of normal without haemolysis or known chronic
liver disease.
2.5. Recruitment
Recruitment was at St George's Healthcare NHS Trust in London
from 9 March 2009 to 15 October 2012.
2.6. Interventions
Patients received two weeks of experimental medication (artesunate
or placebo) just before surgery and standard care. Artesunate (Arinate®
100 mg) was manufactured by Famar Italia S.p.A and matching pla-
cebo tablets were manufactured by MPF in The Netherlands under amanufacturing licence in accordance with EU cGMP certiﬁed by
Dafra Pharma (Belgium). Study medication was packaged, labelled
and certiﬁed by B&C CliniPack (Belgium) and was in pack sizes of
30 × 100 mg and was received, stored and dispensed by the Pharmacy
at St George's Healthcare NHS Trust.
The dose of artesunate for the study was 200 mg orally, daily for
fourteen days, with medication stopped 48–72 h prior to surgery.
Medication was provided in blister packs with one patient box pro-
vided 14 doses, sufﬁcient for the duration of the study.
There was no delay in surgery if patients entered into this study, nor
any other change in clinicalmanagement, and the62day rule (requiring
treatment within this time period after conﬁrmation of diagnosis) was
strictly adhered to.
2.7. Outcomes
The primary endpoint of the trial was the presence or absence of
signiﬁcant apoptosis in the epithelial cells of the tumour specimen de-
ﬁned as N7% of cells with apoptotic features.
Secondary outcomes included seven immunohistochemical stains
applied to the parafﬁn-embedded tumour specimens and quantiﬁed
in both epithelial cells and ﬁbroblasts: vascular endothelial growth fac-
tor (VEGF), c-MYC status and EGF-receptor status; microvessel density
determining the quantity of the cluster of differentiation 31 (CD31) pro-
tein; proliferative activity assessed with Ki67 staining and p53 tumour
suppressor protein expression. Each stain in each patient was generally
evaluated in 6microscopic areaswith a semiautomatic system (in a few
cases 7 or 8 areas were evaluated, and in some – especially for ﬁbro-
blasts –measurements less than 6 or no areas could be evaluated).
2.8. Blood Samples
Three blood samples were taken: (1) at baseline, (2) after one
week of medication (following protocol amendment for enhanced
safety monitoring) and (3) after ending the two week medication
(just before surgery). In each sample the safety measures included
assay of potassium, sodium, creatinine, urea, albumin, alkaline phospha-
tase, ALT, bilirubin, haemoglobin, platelet count and white cell count.
Carcinoembryonic antigen (CEA), was monitored where available in pa-
tients at baseline and after randomization.
2.9. Secondary Outcomes
These were measures of safety and tolerability (both clinical and
laboratory) according to conventional criteria assessed by comparing
baseline blood test results and those during or after treatment and anti-
cancer efﬁcacy (with markers described above).
2.9.1. Changes to Outcomes
There were no changes to predeﬁned endpoints.
2.10. Sample Size
An indicative sample size calculation, given the pioneering nature of
this pilot study, was carried out on the primary outcome before starting
the trial based on the assumption that colorectal cancer is unlikely to ex-
hibit signiﬁcant apoptosis if untreated. Most patients in the placebo
group (more than 95%) were anticipated to have less than 7% of cells
with apoptotic features. The majority of patients (greater than 60%) in
the artesunate group were anticipated to have signiﬁcant apoptosis.
This large differencewas derived frompublishedbaseline estimates of ap-
optotic indices (Yamamoto et al., 1998; Ikenaga et al., 1996; Bendardaf
et al., 2003). With equal group sizes a sample size of 2*11 was estimated
to have 80% power and accepting a Type I error of 5% for superiority, bear-
ing in mind that in most pilot studies the aim is to demonstrate proof-of-
concept (Arain et al., 2010) rather than exclusively test a hypothesis.
84 S. Krishna et al. / EBioMedicine 2 (2015) 82–902.11. Randomisation
Subjects were randomised to receive either artesunate or placebo in
equal numbers. Randomisation was performed using a computer-
generated code, and results supplied in opaque and sealed envelopes
by Dafra Pharma. After enrollment and allocation of the next study
number in the series, participants were given their randomization
pack by a pharmacist. Copies of the key to the randomisation codes
were held by the Clinical Trials Pharmacist only and allocation and con-
cealment stepswere performed in Belgium. The codewas not opened to
investigators, patients, data collectors until the data collection ended,
histological results had been analysed and datasets were locked.
2.12. Sequence Generation and Allocation Concealment Mechanism
Study medications were pre-packed in blister packs and consecu-
tively numbered for each participant according to the randomisation
schedule. Each participant was assigned an order number once they
had consented to the study and after eligibility checks, and they re-
ceived the medication pack with the corresponding randomization
number.
2.13. Blinding
It became necessary to unblind the allocation to 2 participants
during the course of the study at the request of the MHRA after receipt
of notiﬁcation of Adverse Events. Blinding wasmaintained for all inves-
tigators and codes were supplied by the Sponsor's ofﬁce (SGUL) to the
MHRA.Assessed for e
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Fig. 1. Patient ﬂow diagram. Assessment for eligibility was recorded after 6 patients had been ra
number of randomised patients (n = 23).2.14. Data Collection and Structure
Immunohistopathological data generated multiple measurements
per individual as the number of slides differed according to the sizes
of the tumours. Each measurement represents an estimate of staining
of cancer cells found on a slide with 0 denoting no staining observed
on a section. Therefore, the dataset inherits a hierarchical structure
with patients at level one and within individual measurements as
level two. With the exception of the three individuals (Fig. 1) there
are no records considered missing for statistical analysis.
2.15. Exploratory Statistical Analysis
The nature of all data variables have been graphically assessed and
summarised accordingly with means/medians standard deviation for
continuous data or proportions for binary data. Correlations were ex-
plored with Spearman's coefﬁcient.
2.16. Immunochemistry Results and Inferential Data Analysis
A random effects (variance components) model was employed for
immunochemistry data to capture their variabilities correctly, given
their inherent hierarchical structures.
Patients were followed-up with CEAmeasurements every 6 months
and annual CT scans for disease recurrence. Time since surgery to the
ﬁrst disease recurrence has been modelled with survival analysis.
Patient CRC06 has been included in survival analysis and although
there were no samples obtained for immunochemistry, the patient
was known to have survived. Patient CRC13 was initially randomisedligibility (n= 47)
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Table 1
Baseline demographic, clinical and laboratory characteristics.
Artesunate
N = 12
Mean (SD)
Placebo
n = 11
Mean (SD)
Numbersa
(artesunate/
placebo)
Demographics 3
Age (y) 69 (11) 66 (14) 12/10
Gender (%, F) 0.58 0.64
Ethnicity (% Caucasians) 0.83 0.82
Height (m) 1.70 (0.12) 1.62 (0.08) 10/9
Weight (kg) 74 (16.7) 75 (66, 85) 11/10
Biochemistry
Sodium (mmol/L) 140 (1)a 139 (2.28) 11/11
Albumin (g/L) 38 (5.7) 36 (5.7) 11/11
ALT (U/L) 23 (8) 24 (10)a 11/11
Bilirubin (μmol/L) 9 (3) 8 (3) 9/11
Creatinine (μmol/L) 73 (23) 65 (15) 9/11
Urea (mmol/L) 5 (2) 5 (1) 9/11
Haematology
Haemoglobin (g/dL) 11.5 (2) 12.2 (2)a 9/11
White Cell count (/L) 5.3 (2.8) 6.7 (2) 9/11
Platelet Count (/L) 370000 (20000)a 31300 (78000) 8/11
Dukes' stage
A 2 2
B 5 3
C1 2 6
C2 1 1
a Numbers of patients contributing to each value are indicated in the last column.
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did not receive any drug (as per protocol analysis). Patient CRC21 was
deemed as missing and sensitivity analysis including them in either
artesunate or placebo groups is provided. The Cox proportional hazard's
(PH) model has been applied to investigate the hazard ratio of diseaseTable 2
Predicted “grand means” of immunohistochemistry results. Results are presented on a linear
which takes into account the variability within individual measurements as well as that of betw
the difference between the grandmeans in the two groups (artesunate–placebo) is greater than
presented in after sensitivity analysis, with skeptical priors presented ﬁrst followed by inform
recipients (EGFR and c-MYC; r = 0.664; 0.026) and for artesunate recipients (EGFR and p53, r
Marker Artesunate Placebo
Mean 95% CrI Mean 95% CrI
Epithelial
cMYC 45 (27, 53) 43 (27, 64)
CD31 8 (3,12) 5 (2,9)
EGFR 32 (12, 58) 27 (9, 45)
p53 25 (5, 45) 18 (3,35)
Tunel 18 (4,32) 20 (7,32)
VEGF 38 (21, 54) 43 (40, 75)
Ki67* 33 (13, 52) 49 (31, 66)
34 (14, 53) 48 (31, 65)
38 (22, 54) 44 (29, 59)
32 (12, 51) 49 (32, 66)
32 (13, 51) 49 (32, 66)
32 (17, 49) 48 (33, 63)
Fibroblast
c-MYC 7 (−7, 21) 19 (7,32)
CD31 13 (−2, 26) 11 (0, 23)
EGFR 0.1 (−0.5, 0.7) 0.4 (0, 0.9)
Ki67 5 (−3, 12) 10 (3,16)
p53 0.7 (−0.8, 2.1) 0.9 (−0.3, 2)
Tunel 3 (0, 5) 4 (1,6)
VEGF 0.2 (−0.02, 0.5) 0.2 (0.1, 0.3)recurrence for artesunate compared with placebo. and their pointwise
95% conﬁdence intervals are provided for each treatment group.
2.17. Statistical Inference
Model based Bayesian analysis and classical frequentist approaches
have been applied as appropriate. Frequentist statistical signiﬁcance is
conventionally associated with p-values less than 0.05with uncertainty
of parameters assessed by the 95% conﬁdence intervals (CI). Parameter
estimates in Bayesian inference are summarised by their posterior
means and the corresponding 95% credible intervals (CrI). Initially, no
prior knowledge was assumed for the parameter that quantiﬁes the
treatment effect, i.e. the difference between the group means in terms
of immunochemistry measurements and the inference that has been
drawn. If prior information exists, then it is appropriate to assess how
the parameter values change based on this evidence. Ki67 and CD31
were the only stains with prior anti-CRC information available (Li
et al., 2007; Jansen et al., 2011). A sensitivity analysis was conducted
with Ki67. Statistical software used included OpenBUGS (Thomas
et al., 2006) STATA (StataCorp. 2013. Stata Statistical Software: Release
13. College Station, TX: StataCorp LP) and R (Team RDC, 2011).
3. Results
3.1. Participant Flow
Fig. 1 summarises patient ﬂows. 12 patients were randomised to re-
ceive artesunate and 11 to placebo. 2 patients did not receive artesunate
despite randomization (one travelled for surgery outside the UK and
could not be followed up, and the drug expiry date for the relevant
batch had been reached when the other patient attended). One
artesunate recipient could not be evaluated for the primary endpointscale by treatment groups with their 95% credible intervals following a Bayesian analysis
een different individuals in the cluster. The probability of an effect is the probability that
0 (and is not a p-value). *For Ki67 all corresponding estimates with informative priors are
ative priors. Results for some epithelial stains were correlated with each other in placebo
= 0.68; p = 0.04, and Tunel and p53 r = 0.87; p = 0.0025).
P of an effect Difference or change Sensitivity analysis (prior)
0.59 2.6 (−22, 26)
0.79 2.6 (−4, 9)
0.66 5.4 (−24, 32)
0.72 7 (−20, 30)
0.4 −2 (−20, 17)
0.45 −5 (−28, 17)
0.11 −16 (−42, 10) N (0, 1000)
Non-informative
0.13 −15 (−40, 10) N (0, 100)
Vaguely informative
0.23 −6 (−22, 10.1) N (0, 10)
Informative
0.08 −18 (−42, 8) N (−15, 1000)
Non-informative
0.08 −18 (−42, 8) N (−15, 100)
Vaguely informative
0.03 −15 (−31, 0) N (−15, 10)
Informative
0.10 −12 (−30, 7)
0.58 1 (−17, 19)
0.21 −0.3 (−1, 1)
0.16 −5 (−15, 5)
0.40 −0.2 (−2.1, 1.2)
0.31 0.8 (−4, 3)
0.52 0.02 (−0.3–0.3)
% positive
Placebo Artesunate
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Fig. 2. 2a Ki67 staining in treatment groups. Individual results for Ki67 epithelial cell
staining (% positive), the grand means in each treatment group as predicted by the ran-
dom effects model and individual predications are displayed. Interquartile intervals are
presented for the rawmeasurements and the 95% credible intervals correspond to the in-
dividual and group predicted means. This analysis has been carried out under missing at
random assumption (MAR) with large uncertainty around the individualmeans of missing
individuals, as expected and shown for 3 individuals randomised to receive artesunate but
not able to be analysed for reasons given in results. These results correspond to non-
informative prior assumption with regards to the difference between the two groups. 2b
Sensitivity analysis to various prior information on the difference between the two groups
with respect to Ki67— the analysis has been justiﬁed by published experimental results.
The probability that the difference between artesunate and placebo is negative remains
high even under a skeptical prior of no effect (0.77).
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ment ended after the planned numbers were randomised.
3.2. Baseline Data
Baseline demographic and clinical characteristics are summarised in
Table 1. There is comparability between groups, including for Dukes'
staging.
3.3. Primary Outcome
55% of placebo recipients and 67% of artesunate treated patients
achieved the primary outcome (patients in whom the proportion of ap-
optotic cells was N7%). In designing this trial, it was assumed that only
≤1/11 patients receiving placebo would have N7% of tumour cells
displaying apoptosis. The unpredicted higher baseline values in placebo
recipients precluded detection of an artesunate effect in the primary
outcome. Staining results for Tunel as a continuous variable are in
Table 2.
3.4. Secondary Outcomes
3.4.1. Immunohistochemistry Analyses
Table 2 presents analysis of immunohistochemistry results. A ran-
dom effects model scaled linearly provides the posterior distributions
of the group means, their 95% CrI and their estimated differences be-
tween groups. The estimated posterior distributions of differences be-
tween treatment groups lie on both sides of 0 for most measurements
suggesting that the two treatment groups do not differ markedly for
most analysed markers.
Interestingly, the probability of a reduction in Ki67 staining after
artesunate is 89–92% (Table 2; a result that is 1–0.11, because Ki67 is
downregulated) using a non-informative prior on the Ki67 difference
between groups and resulting in a posterior difference of−16 (−42,
10) for treatment. A similar result is conﬁrmed if the conﬁdence around
the parameter value is increased as illustrated in Fig. 2a. With an opti-
mistic informative prior for artesunate of−15 (N (−15,10)), the prob-
ability of an artesunate effect increases to 97% (1–0.03; Table 2), by
altering the parameter distributions as summarised in Fig. 2b.
To complete this analysis, we included a skeptical informative prior
for this parameter (N (0, 10)). Despite this, the probability of an
artesunate effect remains at a probability of 0.77 with a true mean
value estimated at−16 (−22,10; Table 2). CD31 also provided a high
probability (0.79) for a treatment effect. Representative immuno-
stainings are shown in Fig. 3.
3.4.2. Survival Analysis
During amedian followup of 42months, therewere 6 recurrences in
the placebo group and 1 recurrence in an artesunate recipient. Fig. 4 il-
lustrates results from a Cox's proportional hazards model. The hazard
ratio of ﬁrst disease recurrence is 0.16 (95% CI (0.02, 1.3)) in the
artesunate group compared with placebo. The survival beyond 2 years
in the artesunate group is estimated at 91% (95% CI (54%, 98%)) whilst
surviving the ﬁrst recurrence in the placebo group is only 57%(95% CI
(28%, 78%)). A full sensitivity analysis for patient CRC21 is given in Sup-
plementary Table 1 and suggests that if this patient was in the
artesunate group without recurrence at 3 years, then a p-value for an
artesunate effect on survival would be p = 0.07 (95% CI 0.02, 1.21).
3.4.3. CEA Levels
Six artesunate and 4 placebo recipients had CEA levels measured be-
fore and after trial medication (and before resection, classiﬁed as re-
duced, stable or increased). No patients with artesunate had increased
CEA levelswhereas 3 patients in the placebo group had increased values
(p = 0.03, Fisher's exact test).3.5. Adverse Events
Six patients (26% for the ITT population) had adverse events (2 se-
vere, Table 3 and Supplementary Table 1). Two adverse events possibly
related to study drug are described in detail. In the remaining 4 cases, 2
complications (anastomotic leaks after surgery) were considered
unlikely to be related to artesunate, and one case of iron-deﬁciency
anaemia (with no neutropaenia) was attributed to underlying disease.
There was one report of nausea. Detailed descriptions of 2 cases of
neutropaenia are given below and illustrated in Fig. 5.
CRC04: An 81 yo 51 kg female presented with anaemia and a change
in bowel habit, and was discovered to have a large, annular ascending
colon, polypoidal, carcinoma that was not producing obstruction on colo-
noscopy. She was randomised to receive artesunate. There was no evi-
dence of metastatic spread on staging scans (CEA = 3 μg/L). Her mid-
treatment review was unremarkable. She returned for surgery and was
found to be anaemic and neutropenic (Fig. 4a). She was transfused, mak-
ing this a Grade 3 adverse event according to CTCAE criteria (v4.0; http://
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Fig. 3. Immunohistochemical staining of biomarkers in colorectal cancer. (a) Detection of apoptotic cells by the Tunel assay, (b) Ki67, (c) p53, (d) EGFR, (e) c-MYC, (f) CD31, (g) VEGF,
(h) negative control (without primary antibody). Magniﬁcation: ×250. For determination of protein expression the UltraVision polymer detection method (kit from Thermo Fisher Sci-
entiﬁc GmbH, Dreieich, Germany) was used as detailed in Supplementary methods. The immunostained slides were scanned by Panoramic Desk (3D Histotech Pannoramic digital slide
scanner, Budapest, Hungary) and interpreted (Quantiﬁcation of immunostained slides) bypanoramic viewer software (NuclearQuant andmembraneQuant, 3DHISTECH) inwhich positive
stained nucleus ormembranewere counted in each deﬁned annotated area. Evaluation parameters included number of overall detected objects (nucleus ormembrane) in each annotated
area, average of positivity and intensity. Nuclear stainings (Ki67, p53, c-MYC, TUNEL) were quantiﬁed using the Nuclear Qant software andMembrane-bound and cytosolic stainingswere
quantiﬁed by the MembraneQuant software (3D histoQuant). Results are in Table 2.
87S. Krishna et al. / EBioMedicine 2 (2015) 82–90evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_
5x7.pdf). Her neutropenia recovered the following day.
She underwent a laparoscopic right-sided hemicolectomy with an
uneventful recovery. She was offered post-operative chemotherapy in
light of hermoderately differentiated pT3, Dukes' stage B adenocarcino-
ma, which she declined. This was deﬁned as a non-severe adverse event
as there was no prolongation in hospitalization.
CRC07: A 79 yo 50 kg lady presented with anaemia, rectal bleeding
and a change in bowel habit in the preceding few months. She had ahistory of endometrial carcinoma and underwent a total abdominal
hysterectomy and bilateral salpingo-oophorectomy followed by radio-
therapy 11 years before.
Colonoscopy conﬁrmed an adenocarcinoma with impassable stric-
ture at the splenic ﬂexure. Staging CT scan of the chest, abdomen and
pelvis excluded metastasis. She was randomised to receive artesunate.
Her CEA was 212 μg/L but fell steeply following artesunate (to a nadir
of 56 μg/L, Fig. 4b) and no other intervention. She had a persistent
thrombocytosis, but she developed anaemia and leucopenia, which
Placebo Artesunate
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Fig. 4. Survival recurrence curves predicted by Cox proportional hazards model. Patient
CRC21 was assumed to be missing completely at random (please see Supplementary
Table 1 for a full sensitivity analysis). In the placebo group 2 patients died within a year
(108, 170) days leaving 10 (83%) in the study, another 2 within the next year (383, 663
days) leaving 8 (66%) in the study and the other two diedwithin the third year of the follow
up (749 and 990, respectively) leaving 50% patients beyond the third year. The only death in
the artesunate group happened after 552 days leaving 9 patients (90%) surviving beyond the
third year. These crude estimates support the estimates from the data above.
88 S. Krishna et al. / EBioMedicine 2 (2015) 82–90was noted on the day of her planned surgery (Fig. 4c). Her pre-
surgical screening carried out 5 days before surgery also showed
anaemia and leucopenia. Her surgery was delayed and after ap-
propriate expert consultation and bone marrow examination her
anaemia was treated with blood transfusions and her persistent
neutropenia with G-CSF, making this also a Grade 3 adverse event
according to CTCAE criteria.
Bone marrow aspiration showed normal erythropoiesis, with dys-
plastic granulopoiesis and maturation arrest. Some myeloid precursors
were vacuolated with nucleocytoplasmic asynchrony, but without ex-
cess myeloblasts. Megakaryocytes were plentiful. There was a slight in-
crease in plasma cells. Findings were consistent with drug induced
myelosuppression.
The neutrophil count rose after 2 days of G-CSF, which was
stopped. The patient underwent a left hemi-colectomy with en
bloc resection of a small segment of involved small bowel and pri-
mary colonic and small bowel anastamosis 11 days after artesunate,
without any post-operative complications, and a fall in platelet
count (Fig. 4c). The adenocarcinoma was staged as a Dukes' C1 and
T4abN2M0. The tumour was found to be poorly differentiated signet
ring type adenocarcinoma with extramural vascular invasion. She
was advised to have adjuvant chemotherapy as the risk of recur-
rence was ~50%. She declined and opted for surveillance alone.
After 3 years of follow up she is conﬁrmed to be symptom and dis-
ease free and continues to lead an independent life.Table 3
Adverse events. For treatment allocations, please see Fig. 2a.
Study number Event Due to pre-existing illness
CRC 004 Neutropaenia and anaemia No
CRC 007 Neutropaenia and anaemia No
CRC 017 Nausea, but no vomiting No
CRC 018 Anastomotic leak No
CRC 019 Anastomotic leak No
CRC 022 Anaemia Yes4. Discussion
This is the ﬁrst randomised, double blind study to test the anti-CRC
properties of oral artesunate. Escape from apoptosis is a hallmark of tu-
mour cells (Fiandalo and Kyprianou, 2012), with higher apoptotic indi-
ces being associated with more aggressive CRCs (Alcaide et al., 2013).
The pre-deﬁned primary endpoint (proportion of patients with N7%
Tunel positive staining of tumour cells) after artesunate treatment
was not informative, perhaps because an unexpectedly high proportion
(55%) of placebo recipients exceeded the pre-deﬁned threshold. Never-
theless, several secondary endpoints have given encouraging results,
despite limitations of a small study size and an inherent variability in
quantitating immunohistochemical markers.
Artesunate has a very high probability (0.97, calculated with an in-
formative prior in Bayesian analysis, Fig. 2b) of effect on Ki67 staining
of tumour cells. This is consistent with a high probability of artesunate
effect on Ki67 staining of ﬁbroblasts (0.84; Table 2). Ki67 is a marker
of tumour cell proliferation whose upregulation is associated with a
poorer prognosis in colorectal cancer. Other markers of tumour biology
were also affected by artesunate, although with lower probabilities (for
example, 0.79 probability for increased CD31 expression). In one case
(Fig. 4b) there was a ~75% fall in circulating CEA levels after 2 weeks
of artesunate treatment alone.
The recurrence-free survival probability was also higher after
artesunate compared with placebo (at 3 years 0.89 compared with
0.5; Fig. 3) although conﬁdence intervals for these estimates overlap
(HR 0.16, p=0.091, Supplementary Table 1) because of the small num-
bers of patients and therefore events included in this study. Till this
analysis, there have been no deaths in artesunate recipients (despite
some patients having relatively poor prognosis), and 3 deaths in place-
bo recipients.
Two patientswhowere at the lowerweight limit for inclusion in this
study (50 kg, giving an effective dose of 4 mg/kg of artesunate/day)
developed leucopenia (Fig. 4). In one case this reversed shortly after
stopping artesunate, whereas in the other G-CSF may have hastened
recovery. Bone-marrow examination suggested a toxic effect of arte-
sunate. These ﬁndings are consistent with the recent observations in
malaria of a dose-dependent neutropenia with artesunate (N4 mg/kg)
(Bethell et al., 2010), although bone marrow examinations have not
been carried out before. We instituted mid-treatment monitoring for
neutropenia after observations onmalaria but did not note this compli-
cation in other patients. Artesunate associated leucopenia may be dose-
dependent in cancer patients as it is in malaria, and although delayed
haemolysis has been observed after artemisinin use (Rolling et al.,
2014, 2012) it was not a complication in our patients. In future studies,
it may be safer to restrict daily dose of artesunate to b4 mg/kg and to
monitor for haematological complications. A recent publication on
an artesunate dose-ﬁnding study in metastatic breast cancer disease
suggests that 200 mg once a day can be tolerated for up to 3 weeks
(Ericsson et al., 2014).
Liver recurrence was commonest in our patients, followed by perito-
neal and ovarian sites, suggesting that seeding is mainly haematogenous
and trans-peritoneal. As patients had clear circumferential and longitudi-
nal margins at surgery, and detectable metastases were not identiﬁed atRelated to study drug Serious? Study treatment Outcome
Possibly N Resolved
Possibly Y Stopped Resolved
Possibly N Continued unchanged Resolved
Not related Y Resolved
Unlikely Y Stopped Resolved
Unlikely N Continued unchanged Resolved
Fig. 5.Adverse events. a. Patient CRC 04's haemoglobin (ﬁlled red circles, g/dl), total white
cell count (ﬁlled blue squares, ×10−9/L), neutrophil count (green triangles, ×10−9/L) and
platelet count (grey diamonds, x) are shown from the start of the study (Day 0). b. CRC
07's serum carcinoembryonic antigen levels are shown from the start of the study (Day
0). c. CRC 07's haematological results are shown from the start of the study (Day 0) with
symbols as in a. Tx is transfusion of red cells.
89S. Krishna et al. / EBioMedicine 2 (2015) 82–90randomisation, it is likely that micrometastases spread through vascular
invasion (VI) caused recurrence. Previous experience suggests that VI pre-
dicts decreased survival in CRC (Ganapathi et al., 2011; Liang et al., 2007;
Talbot et al., 1980; Betge et al., 2012). Patients with cryptic disseminationof CRC may beneﬁt from systemic neo-adjuvant therapy and artesunate
may be particularly suitable because it does not usually delay surgery. It
also reduces liver metastases in an animal model (Li et al., 2007).
These observations provide critical information for the design of fur-
ther studies. In assessing its neo-adjuvant properties, we have also ex-
amined artesunate's mechanisms of action in human CRC. Artesunate
does not restore apoptosis in tumour cells in our study, but rather de-
creases the expression of a Ki67. Ki67 is also an important marker of
prognosis in CRC unlike CD31, which is increased in expression. These
ﬁndings are consistent with uncontrolled observationsmade in cervical
cancer (Jansen et al., 2011), where decreased Ki67 stainingwas also ob-
served, although decreased CD31 staining of blood vessels in that study
contrasts with our observations. Detailed laboratory observations on
anti-cancer mechanisms of artesunate such as on proliferation (Efferth
et al., 2007, 2003; Yeung et al., 2013) and expression of tumour cell
markers (Konkimalla et al., 2009; Efferth et al., 2004; Konkimalla and
Efferth, 2010) (including for angiogenesis) can now be interpreted in
light of in vivo observations. Larger clinical studies with artesunate
that aim to provide well tolerated and convenient anticancer regimens
should be implemented, and may provide an intervention where
none is currently available, as well as synergistic beneﬁts with current
regimens.
Funding and Acknowledgements
Artesunate and placebo were donated by Dafra Pharma (Turnhout,
Belgium). We thank Dr. Jan Poliniecki for sample size estimations and
statistical support to the Data Safety Monitoring Committee, Mr.
Nikolaos Katsoulas for clinical support andMrs. Doris Rohr for technical
assistance with immunohistochemistry. This study did not receive any
direct funding. MEMS was funded by a PhD stipend from the National
Research Council, Sudan. This study is dedicated to the memory of
Yasmin Krishna.
Author contributions
SK andHJ conceived the study anddesigned it togetherwith PGK,DK
and TE; ICS carried out statistical analysis, SG, MC, DK and SK recruited
andmanaged patients; HKmanaged the study; CF provided clinical histo-
pathological analysis; TE andMEMS analysed immunohistochemistry; SK
wrote the ﬁrst draft to which all authors contributed to produce the ﬁnal
version. No author declares a conﬂict of interest.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2014.11.010.
References
Alcaide, J., Funez, R., Rueda, A., et al., 2013. The role and prognostic value of apoptosis in
colorectal carcinoma. BMC Clin. Pathol. 13 (1), 24.
Anfosso, L., Efferth, T., Albini, A., Pfeffer, U., 2006. Microarray expression proﬁles
of angiogenesis-related genes predict tumor cell response to artemisinins.
Pharmacogenomics J. 6 (4), 269–278.
Arain, M., Campbell, M.J., Cooper, C.L., Lancaster, G.A., 2010. What is a pilot or feasibility
study? A review of current practice and editorial policy. BMC Med. Res. Methodol.
10, 67.
Bendardaf, R., Ristamaki, R., Kujari, H., et al., 2003. Apoptotic index and bcl-2 expression as
prognostic factors in colorectal carcinoma. Oncology 64 (4), 435–442.
Berger, T.G., Dieckmann, D., Efferth, T., et al., 2005. Artesunate in the treatment of metastatic
uveal melanoma—ﬁrst experiences. Oncol. Rep. 14 (6), 1599–1603.
Betge, J., Pollheimer, M.J., Lindtner, R.A., et al., 2012. Intramural and extramural vascular
invasion in colorectal cancer: prognostic signiﬁcance and quality of pathology
reporting. Cancer 118 (3), 628–638.
Bethell, D., Se, Y., Lon, C., et al., 2010. Dose-dependent risk of neutropenia after 7-day
courses of artesunate monotherapy in Cambodian patients with acute Plasmodium
falciparum malaria. Clin. Infect. Dis. 15, e105–e114.
Breuer, E., Efferth, T., 2014. Treatment of iron-loaded veterinary sarcoma by Artemisia
annua. Nat. Prod. Bioprospect. 4, 113–118.
Efferth, T., Rucker, G., Falkenberg, M., et al., 1996. Detection of apoptosis in KG-1a leuke-
mic cells treated with investigational drugs. Arzneimittelforschung 46 (2), 196–200.
90 S. Krishna et al. / EBioMedicine 2 (2015) 82–90Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H., Chitambar, C.R., 2001. The anti-malarial
artesunate is also active against cancer. Int. J. Oncol. 18 (4), 767–773.
Efferth, T., Sauerbrey, A., Olbrich, A., et al., 2003. Molecular modes of action of artesunate
in tumor cell lines. Mol. Pharmacol. 64 (2), 382–394.
Efferth, T., Ramirez, T., Gebhart, E., Halatsch, M.E., 2004. Combination treatment of glio-
blastoma multiforme cell lines with the anti-malarial artesunate and the epidermal
growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol. 67
(9), 1689–1700.
Efferth, T., Giaisi, M., Merling, A., Krammer, P.H., Li-Weber, M., 2007. Artesunate induces
ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2 (8),
e693.
Ericsson, T., Blank, A., von Hagens, C., Ashton, M., Abelo, A., 2014. Population pharmacoki-
netics of artesunate and dihydroartemisinin during long-term oral administration of
artesunate to patients with metastatic breast cancer. Eur. J. Clin. Pharmacol. 70,
1453–1463.
Ferlay, J., Soerjomataram, I., Ervik, M., et al., 2012. GLOBOCAN 2012 v1.0, Cancer Incidence
and Mortality Worldwide: IARC CancerBase No. 11 [Internet], (accessed 11 July
2014).
Fiandalo, M.V., Kyprianou, N., 2012. Caspase control: protagonists of cancer cell apoptosis.
Exp. Oncol. 34 (3), 165–175.
Ganapathi, S., Kumar, D., Katsoulas, N., et al., 2011. Colorectal cancer in the young: trends,
characteristics and outcome. Int. J. Color. Dis. 26 (7), 927–934.
Gomes, M.F., Faiz, M.A., Gyapong, J.O., et al., 2009. Pre-referral rectal artesunate to prevent
death and disability in severe malaria: a placebo-controlled trial. Lancet 373 (9663),
557–566.
Hien, T.T., Arnold, K., Vinh, H., et al., 1992. Comparison of artemisinin suppositories with
intravenous artesunate and intravenous quinine in the treatment of cerebral malaria.
Trans. R. Soc. Trop. Med. Hyg. 86, 582–583.
Hien, T.T., Arnold, K., Hung, N.G., et al., 1994. Single dose artemisinin–meﬂoquine treat-
ment for acute uncomplicated malaria. Trans. R. Soc. Trop. Med. Hyg. 88, 688–691.
Ikenaga, M., Takano, Y., Saegusa, M., et al., 1996. Apoptosis of colon cancers assessed by in
situ DNA nick end-labeling method. Pathol. Int. 46 (1), 33–37.
Jansen, F.H., Adoubi, I., Comoe, J.C., et al., 2011. First study of oral artenimol-R in advanced
cervical cancer: clinical beneﬁt, tolerability and tumor markers. Anticancer Res. 31
(12), 4417–4422.
Jiang, J.B., Li, G.Q., Guo, X.B., Kong, Y.C., Arnold, K., 1982. Antimalarial activity of meﬂo-
quine and qinghaosu. Lancet ii, 285–288.
Konkimalla, V.B., Efferth, T., 2010. Inhibition of epidermal growth factor receptor over-
expressing cancer cells by the aphorphine-type isoquinoline alkaloid, dicentrine.
Biochem. Pharmacol. 79 (8), 1092–1099.
Konkimalla, V.B., McCubrey, J.A., Efferth, T., 2009. The role of downstream signaling path-
ways of the epidermal growth factor receptor for artesunate's activity in cancer cells.
Curr. Cancer Drug Targets 9 (1), 72–80.
Kremsner, P.G., Krishna, S., 2004. Antimalarial combinations. Lancet 364, 285–294.Kremsner, P.G., Taylor, T., Issifou, S., et al., 2012. A simpliﬁed intravenous artesunate reg-
imen for severe malaria. J. Infect. Dis. 205 (2), 312–319.
Krishna, S., Bustamante, L., Haynes, R.K., Staines, H.M., 2008. Artemisinins: their growing
importance in medicine. Trends Pharmacol. Sci. 29 (10), 520–527.
Li, L.N., Zhang, H.D., Yuan, S.J., Tian, Z.Y., Wang, L., Sun, Z.X., 2007. Artesunate attenuates
the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-
catenin pathway. Int. J. Cancer 121 (6), 1360–1365.
Liang, P., Nakada, I., Hong, J.W., et al., 2007. Prognostic signiﬁcance of immuno-
histochemically detected blood and lymphatic vessel invasion in colorectal carcinoma:
its impact on prognosis. Ann. Surg. Oncol. 14 (2), 470–477.
Nealon, C., Dzeing, A., Muller-Romer, U., et al., 2002. Intramuscular bioavailability and
clinical efﬁcacy of artesunate in gabonese children with severe malaria. Antimicrob.
Agents Chemother. 46 (12), 3933–3939.
Rolling, T., Schmiedel, S., Wichmann, D., Wittkopf, D., Burchard, G.D., Cramer, J.P., 2012.
Post-treatment haemolysis in severe imported malaria after intravenous artesunate:
case report of three patients with hyperparasitaemia. Malar. J. 11, 169.
Rolling, T., Agbenyega, T., Issifou, S., et al., 2014. Delayed hemolysis after treatment with
parenteral artesunate in African children with severe malaria—a double-center pro-
spective study. J. Infect. Dis. 209 (12), 1921–1928.
Rutteman, G.R., Erich, S.A., Mol, J.A., et al., 2013. Safety and efﬁcacy ﬁeld study of
artesunate for dogs with non-resectable tumours. Anticancer Res. 33 (5), 1819–1827.
Singh, N.P., Panwar, V.K., 2006. Case report of a pituitary macroadenoma treated with
artemether. Integr. Cancer Ther. 5 (4), 391–394.
Singh, N., Verma, K., 2002. Case report of a laryngeal squamous cell carcinoma treated
with artesunate. Arch. Oncol. 2002, 279–280.
Talbot, I.C., Ritchie, S., Leighton, M.H., Hughes, A.O., Bussey, H.J., Morson, B.C., 1980. The
clinical signiﬁcance of invasion of veins by rectal cancer. Br. J. Surg. 67 (6), 439–442.
Team RDC, 2011. R: A Language and Environment for Statistical Computing. http://www.
R-project.org/ (accessed 12 July 2014).
Thomas, A., O' Hara, R., Ligges, U., Sturtz, S., 2006. Making BUGS open. R News 6 (1),
12–17.
UK CR, 2014. Bowel Cancer Statistics. http://www.cancerresearchuk.org/cancer-info/
cancerstats/types/bowel/ (accessed 11 July 2014).
Yamamoto, T., Igarashi, N., Kato, Y., Kobayashi, M., Kawakami, M., 1998. Apoptosis in
adenoma and early adenocarcinoma of the colon. Histol. Histopathol. 13 (3), 743–749.
Yeung, T.M., Buskens, C., Wang, L.M., Mortensen, N.J., Bodmer, W.F., 2013. Myoﬁbroblast
activation in colorectal cancer lymph node metastases. Br. J. Cancer 108 (10),
2106–2115.
Zhang, Z.Y., Yu, S.Q., Miao, L.Y., et al., 2008. Artesunate combined with vinorelbine
plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized
controlled trial. Zhong Xi Yi Jie He Xue Bao 6 (2), 134–138.
